CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA
Executive Summary
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.
You may also be interested in...
PCPC Legal Head Tom Myers Steps Into President, CEO Role In 2024
Personal Care Products Council VP for legal and regulatory affairs and general counsel, Tom Myers, will take over as president and CEO of the US trade association when long-time head Lezlee Westine steps down at the end of the year, the association announced on 15 November.
US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags
Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.
PCPC Hatching Proposal For CIR Role In FDA Ingredient Review
The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.